What is the new agreement between Lumos Diagnostics (ASX:LDX) and Micro-Pak?

Lumos Diagnostics has signed a three-year contract manufacturing agreement to produce the Micro-Pak Mold Analyzer system. This marks a strategic transition for Lumos from the product development phase into active commercial manufacturing.

How much is the first purchase order for Lumos Diagnostics (ASX:LDX) worth?

Lumos has received an initial purchase order valued at US$250,000 under the new three-year agreement. This order provides immediate revenue momentum and serves as a proof-of-concept for the commercial viability of the partnership.

What is the Micro-Pak Mold Analyzer system produced by Lumos (ASX:LDX)?

The system is a diagnostic hardware suite consisting of a proprietary rapid test cassette, a custom digital camera reader, and a mobile application. It is engineered to detect 56 different mould species on-site, providing a faster alternative to traditional laboratory analysis.

Why is this manufacturing contract a milestone for Lumos Diagnostics (ASX:LDX)?

This agreement represents a successful pivot from the "developer" stage to the "manufacturer" stage for this specific product line. By moving into contract manufacturing, Lumos can generate recurring revenue through its Commercial Services Division rather than relying solely on one-off development fees.

What are the key bull points for Lumos Diagnostics (ASX:LDX) after this news?

The primary bull case is the shift toward stable, multi-year manufacturing revenue and the validation of Lumos's point-of-care diagnostic expertise. The partnership with Micro-Pak, a leader in moisture prevention, gives Lumos access to a global supply chain market beyond healthcare.

What are the main risks for investors considering Lumos Diagnostics (ASX:LDX)?

As a micro-cap stock trading at $0.21, Lumos faces typical risks associated with scaling production and maintaining margins on hardware. There is a risk that future purchase orders may not scale as quickly as anticipated or that the company may face competition from other rapid-testing technologies.

Lumos secures Micro-Pak manufacturing deal and order

Written by Brie CarterPublished Apr. 8 2026Last Updated Apr. 8 2026

Lumos Diagnostics (ASX:LDX) has transitioned from developer to manufacturer for Micro-Pak, announcing a new three-year contract manufacturing agreement for the innovative Micro-Pak Mold Analyser system.

The follow-on contract, managed by the Lumos Commercial Services Division, marks a milestone in the commercialisation of a technology designed to revolutionise moisture and mould prevention across global supply chains.

Alongside the agreement, Lumos confirmed the receipt of an initial purchase order valued at US$250,000, signalling immediate momentum for the partnership.

The Mold Analyzer system represents a breakthrough in diagnostic hardware, comprising a proprietary rapid test cassette, a custom digital camera reader, and a dedicated mobile application.

Engineered by Lumos, the system is the first of its kind capable of detecting 56 distinct mould species, offering broad-spectrum coverage for both professional industrial environments and home consumer use.

By facilitating rapid on-site detection, the technology significantly reduces the turnaround times typically associated with traditional laboratory-based analysis.

For manufacturers, the integration of the Lumos digital reader ensures full traceability and consistent testing standards from the factory floor to the end consumer.

Alternatively, the system can be configured as a stand-alone visual test, providing a low-cost entry point for domestic mould monitoring.

The partnership leverages Micro-Pak’s market leadership in product protection and Lumos’s expertise in point-of-care diagnostics.

At the time of reporting, Lumos Diagnostics’ share price was $0.21.